Insider Trading Alert - CLCT, MDCO And LQ Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 10, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $6.99 to $188,811,000.00.

Highlighted Stocks Traded by Insiders:

Collectors Universe (CLCT) - FREE Research Report

Wallace Joseph John, who is Chief Financial Officer at Collectors Universe, sold 1,527 shares at $22.25 on June 10, 2015. Following this transaction, the Chief Financial Officer owned 99,511 shares meaning that the stake was reduced by 1.51% with the 1,527-share transaction.

The shares most recently traded at $21.41, down $0.84, or 3.93% since the insider transaction. Historical insider transactions for Collectors Universe go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 60,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 109,793

The average volume for Collectors Universe has been 23,000 shares per day over the past 30 days. Collectors Universe has a market cap of $194.5 million and is part of the services sector and diversified services industry. Shares are up 4.75% year-to-date as of the close of trading on Wednesday.

Collectors Universe Inc. provides third-party authentication, grading, and related services for rare and high-value collectibles consisting of coins, trading cards, sports memorabilia, and autographs. The stock currently has a dividend yield of 6.39%. The company has a P/E ratio of 23.1. Currently, there are no analysts who rate Collectors Universe a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLCT - FREE

TheStreet Quant Ratings rates Collectors Universe as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Collectors Universe Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medicines Company (MDCO) - FREE Research Report

Shigeta Hiroaki, who is Director at Medicines Company, sold 7,500 shares at $28.99 on June 10, 2015. Following this transaction, the Director owned 23,970 shares meaning that the stake was reduced by 23.83% with the 7,500-share transaction.

The shares most recently traded at $29.05, up $0.06, or 0.21% since the insider transaction. Historical insider transactions for Medicines Company go as follows:

  • 4-Week # shares sold: 1,281
  • 12-Week # shares sold: 36,054
  • 24-Week # shares sold: 43,608

The average volume for Medicines Company has been 1.1 million shares per day over the past 30 days. Medicines Company has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 4.95% year-to-date as of the close of trading on Wednesday.

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. Currently, there are 2 analysts who rate Medicines Company a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDCO - FREE

TheStreet Quant Ratings rates Medicines Company as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Medicines Company Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

La Quinta Holdings (LQ) - FREE Research Report

Lombardi Angelo J., who is Officer at La Quinta Holdings, sold 35,558 shares at $24.30 on June 10, 2015. Following this transaction, the Officer owned 89,576 shares meaning that the stake was reduced by 28.42% with the 35,558-share transaction.

The shares most recently traded at $24.40, up $0.10, or 0.41% since the insider transaction. Historical insider transactions for La Quinta Holdings go as follows:

  • 4-Week # shares sold: 35,577
  • 12-Week # shares sold: 158,876
  • 24-Week # shares sold: 408,391

The average volume for La Quinta Holdings has been 1.2 million shares per day over the past 30 days. La Quinta Holdings has a market cap of $3.2 billion and is part of the services sector and leisure industry. Shares are up 10.43% year-to-date as of the close of trading on Wednesday.

La Quinta Holdings Inc. owns, operates, and franchises select-service hotels under the La Quinta brand. It serves the upper-midscale and midscale segments. Currently, there are 6 analysts who rate La Quinta Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LQ - FREE

TheStreet Quant Ratings rates La Quinta Holdings as a sell. Among the areas we feel are negative, one of the most important has been very high debt management risk by most measures. Get the full La Quinta Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

3 Buy-Rated Dividend Stocks Leading The Pack: CLCT, PFLT, AB

3 Buy-Rated Dividend Stocks Leading The Pack: CLCT, PFLT, AB

Top 3 Yielding Buy-Rated Stocks: OFS, LOAN, CLCT

Top 3 Yielding Buy-Rated Stocks: OFS, LOAN, CLCT

3 Buy-Rated Dividend Stocks: PFLT, AB, CLCT

3 Buy-Rated Dividend Stocks: PFLT, AB, CLCT

3 Buy-Rated Dividend Stocks: OFS, BKCC, CLCT

3 Buy-Rated Dividend Stocks: OFS, BKCC, CLCT

Insider Trading Alert - CLCT, ECR And TECD Traded By Insiders

Insider Trading Alert - CLCT, ECR And TECD Traded By Insiders